PUBLISHER: The Insight Partners | PRODUCT CODE: 1510753
PUBLISHER: The Insight Partners | PRODUCT CODE: 1510753
The Middle East & Africa malaria treatment market was valued at US$ 2,091.28 million in 2022 and is expected to reach US$ 15,512.97 million by 2030; it is estimated to grow at a CAGR of 28.5% from 2022 to 2030.
Extending Pipeline of New Drugs and Vaccines Fuels Middle East & Africa Malaria Treatment Market
Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options. Therefore, the growing number of antimalarial and drugs/vaccines that are under clinical development are expected to boost the market growth in the future.
A few antimalarial that are under clinical development are mentioned in the table below:
Drug Developer Clinical Trial Stage
Artefenomel Sanofi Phase IIb
KAE609 Novartis AG Phase IIb
KAF156 Novartis AG Phase IIb
DSM265 Takeda Pharmaceutical Company Phase IIa
SANARIA PfSPZ-GA1 Sanaria Phase II
SANARIA PfSPZ Vaccine - Radiation Attenuated PfSPZ Vaccine Sanaria Phase II
SANARIA PfSPZ-CVac Sanaria Phase II
MSP3-CRM-Vac4All Vac4All Phase I
Liver-Stage Antigen-3 (LSA3) Vac4All Phase IIa
Source: Company Website, The Insight Partners Analysis
Therefore, the growing number of antimalarial and drugs/vaccines that are under clinical development are expected to boost the market growth in the future.
Middle East & Africa Malaria Treatment Market Overview
The malaria treatment market in the Rest of Middle East & Africa is segmented into Israel, Iran, Iraq, Kuwait, Oman, Egypt, Quatar, and others. The Mediterranean Journal of Hematology and Infectious Diseases report states that imported malaria poses a serious health problem in Qatar. For example, imported malaria in Qatar increased during the past seven years despite the constant reduction, and the most affected were adult male migrants from endemic countries. Moreover, non-governmental organizations have stepped in to provide health education and preventative tools in countries where malaria is endemic. Furthermore, federal governments have also invested in commercials to educate the public on malaria transmission as well as methods of protection and treatment, which is likely to boost the market for malaria treatment in the Rest of Middle East & Africa.
Middle East & Africa Malaria Treatment Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Malaria Treatment Market Segmentation
The Middle East & Africa malaria treatment market is segmented based on treatment, route of administration, distribution channel, and country. Based on treatment, the Middle East & Africa malaria treatment market is segmented into generic drugs, originators, vaccines, and others. The vaccines segment held the largest market share in 2022.
In terms of route of administration, the Middle East & Africa malaria treatment market is bifurcated into oral and parenteral. The oral segment held a larger market share in 2022.
By distribution channel, the Middle East & Africa malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022.
Based on country, the Middle East & Africa malaria treatment market is segmented into South Africa, Saudi Arabia, the UAE, Kenya, Tanzania, Rwanda, Nigeria, Ghana, Uganda, Angola, Cameroon, Senegal, Zambia, and the Rest of Middle East & Africa. The Rest of Middle East & Africa dominated the Middle East & Africa malaria treatment market share in 2022.
Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, and Lupin Ltd are some of the leading players operating in the Middle East & Africa malaria treatment market.